| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Echinatin, a chalcone derivative named retrochalcone, is a naturally occuring product isolated from the licorice and is a chalcone derivative called retrochalcone. It displays antioxidant properties and anti-inflammatory activities.
| ln Vitro |
In LPS-challenged BMDM, echinatin (0–40 μM, 60 minutes) binds to HSP90 and inhibits ATPase activity, hence suppressing cyclin-induced activation of the NLRP3 regulatory body [2]. In ESCC (KYSE30 and KYSE270 cells), echinatin (0–40 μM, 1–5 days) decreases cell proliferation, migration, and shortening while inducing cell sealing and autophagy [4].
|
|---|---|
| ln Vivo |
Echinatin (20–80 mg/kg, i.p.) is cardioprotective; Echinatin (20 and 50 mg/kg, ischemia) inhibits tumor growth in KYSE270-derived tumor xenografts and inhibits AKT/mTOR buffering [4]. Echinatin (20 and 40 mg/kg, intraperitoneally) inhibits LPS-induced probe septic shock by inhibiting NLRP3 inflammasome activation [2].
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: LPS-primed BMDMs Tested Concentrations: 0- 40 μM Incubation Duration: 60 minutes Experimental Results: diminished production of cleaved caspase-1 and IL-1β. Immunofluorescence [4] Cell Types: KYSE30 and KYSE270 Cell Tested Concentrations: 40 μM Incubation Duration: 2 days Experimental Results: Induced cellular LC3 puncta accumulation. |
| Animal Protocol |
Animal/Disease Models: LPS-induced septic shock in mice [1]
Doses: 20 and 40 mg/kg Route of Administration: intraperitoneal (ip) injection Experimental Results: Inhibited LPS-induced IL-1β and TNF-α production. diminished proportion and number of neutrophils in peritoneal lavage cells in mice. |
| References |
[1]. Liang M, et al. Antioxidant Mechanisms of Echinatin and Licochalcone A. Molecules. 2018 Dec 20;24(1).
[2]. Xu G, et al. Echinatin effectively protects against NLRP3 inflammasome-driven diseases by targeting HSP90. JCI Insight. 2021 Jan 25;6(2):e134601. [3]. Niu J, et al. Cardioprotective Effect of Echinatin Against Ischemia/Reperfusion Injury: Involvement of Hippo/Yes-Associated Protein Signaling. Front Pharmacol. 2021 Jan 11;11:593225. [4]. Hong P, et al. Echinatin suppresses esophageal cancer tumor growth and invasion through inducing AKT/mTOR-dependent autophagy and apoptosis. Cell Death Dis. 2020 Jul 13;11(7):524. |
| Molecular Formula |
C16H14O4
|
|---|---|
| Molecular Weight |
270.2800
|
| CAS # |
34221-41-5
|
| SMILES |
O=C(C1=CC=C(O)C=C1)/C=C/C2=CC=C(O)C=C2OC
|
| InChi Key |
QJKMIJNRNRLQSS-WEVVVXLNSA-N
|
| InChi Code |
InChI=1S/C16H14O4/c1-20-16-10-14(18)8-4-12(16)5-9-15(19)11-2-6-13(17)7-3-11/h2-10,17-18H,1H3/b9-5+
|
| Chemical Name |
(E)-3-(4-hydroxy-2-methoxyphenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one
|
| Synonyms |
Retrochalcone;
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~462.48 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.17 mg/mL (8.03 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 21.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (7.70 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6999 mL | 18.4993 mL | 36.9987 mL | |
| 5 mM | 0.7400 mL | 3.6999 mL | 7.3997 mL | |
| 10 mM | 0.3700 mL | 1.8499 mL | 3.6999 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA